Biocompatible adipose extracellular matrix and reduced graphene oxide nanocomposite for tissue engineering applications.
Verstappen K., Klymov A., Cicuéndez M., da Silva DM., Barroca N., Fernández-San-Argimiro FJ.
Animal Study on Spinal Cord Injury, published in Mater Today Bio (2024) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Animal Study
- Journal
- Mater Today Bio (2024)
- Country
- England
- Reported sample size
- —
- Source database
- PubMed
- PMID
- 38693996
- DOI
- 10.1016/j.mtbio.2024.101059
Abstract (original English)
Despite the immense need for effective treatment of spinal cord injury (SCI), no successful repair strategy has yet been clinically implemented. Multifunctional biomaterials, based on porcine adipose tissue-derived extracellular matrix (adECM) and reduced graphene oxide (rGO), were recently shown to stimulate in vitro neural stem cell growth and differentiation. Nevertheless, their functional performance in clinically more relevant in vivo conditions remains largely unknown. Before clinical application of these adECM-rGO nanocomposites can be considered, a rigorous assessment of the cytotoxicity and biocompatibility of these biomaterials is required. For instance, xenogeneic adECM scaffolds could still harbour potential immunogenicity following decellularization. In addition, the toxicity of rGO has been studied before, yet often in experimental settings that do not bear relevance to regenerative medicine. Therefore, the present study aimed to assess both the in vitro as well as in vivo safety of adECM and adECM-rGO scaffolds. First, pulmonary, renal and hepato-cytotoxicity as well as macrophage polarization studies showed that scaffolds were benign in vitro . Then, a laminectomy was performed at the 10th thoracic vertebra, and scaffolds were implanted directly contacting the spinal cord. For a total duration of 6 weeks, animal welfare was not negatively affected. Histological
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.
Related research
- Level ASystematic ReviewPubMed
Host immune determinants of stromal vascular fraction graft survival: Toward a concept of SVF therapy resistance - A systematic narrative review.
Systematic Review on Spinal Cord Injury, Chronic Inflammation, Immune Modulation, published in Cell Transplant (2026) — summary generated from the PubMed abstract.
- 2026
Cell Transplant - Level AMeta-analysisPubMed
Stem cell-derived exosome treatment for acute spinal cord injury: a systematic review and meta-analysis based on preclinical evidence.
Meta-analysis on Spinal Cord Injury, published in Front Neurol (2025) — summary generated from the PubMed abstract.
- 2025
Front Neurol - Level ASystematic ReviewPubMed
Brain-derived neurotrophic factor (BDNF) as biomarker in stem cell-based therapies of preclinical spinal cord injury models: A systematic review.
Systematic Review on Spinal Cord Injury, published in Tissue Cell (2025) — summary generated from the PubMed abstract.
- 2025
Tissue Cell3 citations - Level ASystematic ReviewEurope PMC
Revolutionizing neural regeneration with smart responsive materials: Current insights and future prospects
Systematic Review on Spinal Cord Injury, published in Bioact Mater (2025) — summary generated from the PubMed abstract.
- 2025
Bioact Mater5 citations - Level ASystematic ReviewEurope PMC
Conductive Nanocomposite Hydrogels for Neural Tissue Engineering: A Systematic Scoping Review of Recent Trends
Systematic Review with a reported sample of 42 on Diabetic Foot, Stroke Research, Spinal Cord Injury, Neuroinflammation, published in Adv Sci (Weinh) (2025) — summary generated from the PubMed abstract.
- 2025
- n = 42
Adv Sci (Weinh)18 citations - Level ASystematic ReviewEurope PMC
Emerging regenerative strategies for spinal cord injury: exosome-derived mechanisms and therapeutic insights
Systematic Review on Spinal Cord Injury, Neuroinflammation, published in Front Neurosci (2025) — summary generated from the PubMed abstract.
- 2025
Front Neurosci